What Does MediWound Do?

Total employees115
HeadquartersYavne
Founded2000

MediWound Ltd. is a fully-integrated biopharmaceutical company focused on developing, manufacturing, and commercializing innovative, cost-effective biotherapeutic solutions for tissue repair and regeneration. Their core mission is to address unmet medical needs in the fields of severe burn care and chronic wound management. Key products include NexoBrid®, an orphan biologic drug for eschar removal in adults with deep partial and full-thickness thermal burns, and EscharEx®, an investigational biological drug candidate for the debridement of chronic and other hard-to-heal wounds. MediWound leverages its enzymatic technology platform and robust R&D pipeline to provide novel treatments that aim to improve clinical outcomes and enhance the quality of life for patients worldwide.

Where Is MediWound's Headquarters?

HQ Function

The Yavne headquarters serves as the company's principal executive, administrative, research and development (R&D), and manufacturing center for its portfolio of biopharmaceutical products.

Notable Features:

The facility is equipped with advanced laboratories for cutting-edge R&D and cGMP-compliant manufacturing suites designed to meet stringent international pharmaceutical standards.

Work Culture:

MediWound cultivates a work culture centered on innovation, collaboration, and scientific rigor. Employees are driven by a shared commitment to advancing medical science and making a tangible difference in patients' lives.

HQ Significance:

This central hub is pivotal to MediWound's entire value chain, from initial drug discovery and clinical development to global manufacturing, commercial strategy, and corporate governance.

Values Reflected in HQ: The headquarters embodies MediWound's core values of innovation, quality, patient-centricity, and dedication to scientific excellence in addressing challenging medical conditions.

Location:

MediWound supports its global operations from its headquarters in Israel and its European office in Germany. The company's products are commercialized in multiple international markets through a combination of direct sales efforts and strategic partnerships with leading healthcare companies. For instance, NexoBrid® is commercialized in North America by Vericel Corporation. MediWound actively conducts clinical trials in various countries to expand product indications and secure regulatory approvals, thereby broadening its international market reach and patient access.

Street Address:

42 Hayarkon Street

City:

Yavne

State/Province:

Central District

Country:

Israel

Where Else Does MediWound Operate Around the World?

Mannheim, Baden-Württemberg, Germany

Address: Augusta Anlage 33, 68165 Mannheim, Germany

To support the commercialization and distribution of MediWound's products across Europe, engage with European healthcare professionals and regulatory bodies, and manage regional partnerships.

Buying Intent Signals for MediWound

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading MediWound? Meet the Executive Team

As of April 2025, MediWound' leadership includes:

Ofer Gonen - Chief Executive Officer
Boaz Gur-Lavie - Chief Financial Officer
Robert J. Snyder, DPM, MBA, MSc, CWSP, FFPM RCPS (Glasgow) - Chief Medical Officer
Prof. Lior Rosenberg, M.D. - Chief Medical Technology Advisor
Eran Cohen - VP Operations
Hila Haviv Keren - VP Regulatory Affairs and Quality Assurance
Dr. Yael Hazan, PhD - VP Research & Development

Who's Investing in MediWound?

MediWound has been backed by several prominent investors over the years, including:

Clal Biotechnology Industries Ltd. (CBI)
Various institutional investors and funds

What Leadership Changes Has MediWound Seen Recently?

Hire2
Exits1

MediWound has seen key leadership transitions in the past year, notably with the appointment of a new CEO and a new CFO to steer the company's strategic growth and financial operations.

Departures

Sharon Malka, Sharon Malka departed from the role of Chief Executive Officer.

New Appointments:

Ofer Gonen, Ofer Gonen was appointed as the new Chief Executive Officer of MediWound.
Boaz Gur-Lavie, Boaz Gur-Lavie was appointed as the new Chief Financial Officer.

What Technology (Tech Stack) Is Used byMediWound?

Discover the tools MediWound uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

MediWound Email Formats and Examples

While MediWound Ltd. does not publicly disclose its official email format, a common pattern used by companies of similar size and structure in the biopharmaceutical industry is [first_initial][last]@mediwound.com or [first].[last]@mediwound.com. This is an educated estimation.

[first_initial][last]@mediwound.com

Format

ogonen@mediwound.com

Example

75%

Success rate

What's the Latest News About MediWound?

MediWound Ltd. Press ReleaseApril 29, 2024

MediWound Ltd. Announces First Patient Enrolled in its U.S. Phase III Study of EscharEx® for the Debridement of Venous Leg Ulcers (VLUs)

MediWound reported the enrollment of the first patient in its pivotal U.S. Phase III study (SafeDebride Study) evaluating EscharEx® for the debridement of venous leg ulcers. This marks a significant step in advancing EscharEx® towards potential U.S. market approval....more

MediWound Ltd. Press ReleaseMarch 25, 2024

MediWound Ltd. Reports Full Year 2023 Financial Results and Provides Corporate Update

MediWound announced its financial results for the full year ended December 31, 2023, highlighting key achievements, including progress with NexoBrid® commercialization and EscharEx® development, alongside its financial performance and outlook for 2024....more

MediWound Ltd. Press ReleaseFebruary 20, 2024

MediWound Ltd. Announces U.S. FDA Clearance of NexoBrid® Biologics License Application (BLA) for Eschar Removal in Adults with Deep Partial and/or Full-Thickness Thermal Burns

A landmark achievement for MediWound, the U.S. Food and Drug Administration (FDA) cleared the Biologics License Application (BLA) for NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns. This clearance paves the way for its U.S. launch by Vericel....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including MediWound, are just a search away.